After participating in this educational activity, the participant should be better able to: 1. Evaluate key factors associated with increased risk of hospital acquired bloodstream infections in children. 2. Evaluate the concept of using a treatment bundle to reduce and maintain low prevalence rates for catheter-associated bloodstream infections. Unless otherwise noted below, each faculty or staff's spouse/life partner (if any) has nothing to disclose. The authors have disclosed that the U.S. Food and Drug Administration has not approved helium-oxygen mixtures for the treatment of status asthmaticus discussed in this article. Please consult the products labeling information for approved indications and usage.
C atheter-associated bloodstream infections (CA-BSI) are an enormous problem in pediatric critical care that adversely affect outcome. In this report, Nowak et al convincingly demonstrate increased length of stay and hospital costs in critically ill children with CA-BSI, along with identifying factors associated with increased risk and prevention of these events. Hospital-acquired infections pose a significant burden to the U.S. healthcare system. For example, reliable estimates suggest that there are between 200,000 -400,000 hospital-acquired BSI each year, most of which (Ͼ90%) are associated with the use of intravascular catheter devices (1) . Hospital-acquired BSI are the most frequently reported nosocomial infections in the pediatric intensive care unit (PICU) (2) , with attributable healthcare costs reported as $39,000 -$50,000 per infection (3) (4) (5) . Severity of illness, as determined by admission Pediatric Risk of Mortality (PRISM) score or underlying illnesses, has not been associated with an increased risk of hospital-acquired BSI (1, 6, 7) . The presence of invasive devices, such as arterial catheters (7), indwelling bladder catheters (8, 9) , and central venous catheters (1, 7, 8) , significantly increase the risk of hospital-acquired BSI in the PICU. Importantly, CA-BSI comprise the vast majority of hospital-acquired BSI (1, 10) in hospitalized children. According to the most recent National Healthcare Safety Network report, the pooled mean rate of CA-BSI in 71 medical-surgical PICUs across the United States was 2.9 per 1000 central catheter days (interquartile range [IQR] , 0.0 -3.8) (10) . Although the cost of CA-BSI in terms of annual healthcare expenditures and lives lost in critically ill adults is widely appreciated (11) (12) (13) , the attributable costs of CA-BSI in critically ill children are not currently known. Accordingly, we conducted a retrospective, case-matched (1:1) cohort study to determine whether CA-BSI was associated with increased PICU and hospital length of stay (LOS) and increased healthcare costs in critically ill children.
MATERIALS AND METHODS

Study Design
We conducted a retrospective, case-matched, cohort study comparing the PICU and total hospital LOS and healthcare costs between critically ill children with CA-BSI and their matched controls. Our study was approved by the Institutional Review Board, and due to the retrospective nature of our study, the need for informed consent was waived. We reviewed all cases of CA-BSI occurring in patients admitted to either the PICU or cardiac intensive care unit at our institution between January 2004 and December 2007.
Definition and Identification of CA-BSI Case Patients
We defined CA-BSI according to the Centers for Disease Control and Prevention and National Healthcare Safety Network consensus definitions as a laboratory-confirmed BSI not related to an infection at another site, occurring in a patient with an indwelling central venous catheter during the 48 hrs preceding the infection (14 -16) . We reviewed our Infection Control and PICU databases and identified all patients with documented CA-BSI (case) during the study. One control patient was identified for each case of CA-BSI.
Criteria for Selection and Matching of Non-CA-BSI Control Patients
Controls were matched for age, severity of illness, primary diagnosis, underlying organ system dysfunction, duration of catheter placement, and surgical procedure (if applicable). Patients were matched for age, using one of three predefined age group categories: infant (age, Ͻ24 months), child (age, Ͼ24 months, and Յ12 yrs), or adolescent (age, Ͼ12 yrs). The PRISM II score was used to adjust for severity of illness (17, 18) . A PRISM II score was calculated from data obtained during the first 24 hrs of admission to the PICU and was used to adjust for case-mix severity between cases and controls. Cases were matched with controls for PRISM II scores of Ϯ10 (5). If a case had more than one CA-BSI during their hospitalization, they were matched based on their first CA-BSI episode only.
Data Collection and Measurement
Patient demographic data were collected from the PICU database, including age, gender, primary diagnosis, chronic diagnoses, and surgeries performed. In addition, we calculated the PICU LOS and total hospital LOS, as well as survival to PICU discharge and hospital discharge. Patient financial data for daily hospital costs were obtained for each patient from the hospital accounting database. This costaccounting system includes direct and indirect cost components, which are allocated primarily on a Medicare step-down allocation method (19) . Costs were broken down by categories: blood products, laboratory, other ancillary, pharmacy, professional fees, radiology, respiratory therapy, room and board, supply, and surgery. Costs were summed across each category to provide the total cost for each day and for the entire hospital admission. Costs were accumulated for both the PICU LOS and entire hospital LOS and did not include hospital readmissions. Daily hospital costs were charted graphically for each patient and were annotated with key patient status changes (i.e., date of CA-BSI infection, PICU admission/discharge dates, surgical procedures). The costs and LOS attributable to an occurrence of CA-BSI were calculated as the difference in median costs and median LOS between CA-BSI patients and matched control patients.
To quantify the benefit of reducing the CA-BSI rate, we used a methodology described by Gastmeier et al (20) to estimate the number of prevented device-associated infections. Using the results from our matched case-control study, we estimated the reduction in hospital days and cost savings post implementation of a pediatricspecific CA-BSI prevention bundle in our PICU. Costs to third-party payers were defined as the payments made by payers to the hospital for billed charges. Net revenue to the hospital was defined as payments received from thirdparty payers for billed charges. Cost savings to payers from CA-BSI prevention occurred if CA-BSI-related billings decreased post bundle implementation. Using payer-specific payment/ cost ratios as reported by the American Hospital Association for the aggregate U.S. hospital industry (21), we estimated the incremental payments received due to CA-BSI. Using the American Hospital Association's payment/cost ratios for 2007 and our study population's actual payer mix, we calculated a mean payment/cost ratio of 1.09, or, for every $1.00 of hospital cost, we estimated the hospital received $1.09 from payers. The payment/cost ratio of 1.09 was applied to the reduction in total hospital costs to determine the total cost savings to payers from CA-BSI prevention. To understand and compare the revenue generated during the course of a patient's hospital stay, we analyzed and charted the net revenue generated per day, or net revenue profile, for CA-BSI patients and matched control patients, using their median net revenue and median LOS.
Statistical Analysis
Parametric continuous data were compared, using the Student's t test. Nonparametric continuous data were compared, using the Wilcoxon signed-rank test. Categorical data were compared, using the chi-square test or the Fisher's exact test when the latter was more appropriate. A p Յ .05 was considered statistically significant for all comparisons.
RESULTS
CA-BSI Prevalence
During the study period, 9158 patients were admitted to the PICU and cardiac intensive care unit for a total of 39,121 intensive care days. Nearly half (n ϭ 4064) of these patients had a central venous catheter in place at some point during their intensive care stay, for a total of 26,771 central catheter days. During this study period, 65 CA-BSIs were identified in 61 patients (0.6% of all patients). The CA-BSI rate during the period of study was 2.43 infections per 1000 central catheter days. Twenty-one of the 61 CA-BSI cases were matched with a corresponding control, based on predefined matching criteria. One case matched on all of the aforementioned criteria, with the exception of severity of illness-the PRISM II difference was 11, rather than the prespecified maximum of 10. When reviewing this case and with the lack of other possible controls, we considered this a suitable match, and the patient was included in the study. No suitable match could be identified for the remaining 39 cases. Thus, of the 61 identified CA-BSI patients, 22 were matched and subjected to demographic and financial comparison. All matches were reviewed and approved by the study investigators (J.E.N., R.J.B., and D.S.W.) to ensure appropriate clinical interpretation of the matching criteria. There were no significant differences between the case and control patients with respect to age (median, 49.7 months vs. 70.0 months, p ϭ .685), severity of illness (mean PRISM II, 10.5 Ϯ 6.6 vs. 9.0 Ϯ 5.0, p ϭ .387), or most frequent primary diagnosis (Table 1) .
Attributable LOS, Costs, and Mortality
Collectively, the aggregate hospital LOS was 51% (572 days) longer and hospital costs were 69% ($4,147,774) higher in the patients with a CA-BSI compared with those patients without a CA-BSI (Fig. 1) . Similarly, the aggregate PICU LOS was 43% (212 days) longer and PICU costs were 68% ($2,381,725) higher in the patients with a CA-BSI compared with those patients without a CA-BSI. Patients with CA-BSI had a significantly longer total hospital LOS (median, 31.0 days; IQR, 17.0 -99.0) compared with patients without CA-BSI (median, 22.0 days; IQR, 13.0-67.0; p ϭ .04). Similarly, patients with CA-BSI also had a significantly longer PICU LOS (median, 17.5 days; IQR, 10.0-34.0) compared with patients without CA-BSI (median, 11.0 days; IQR, 6.0-18.0; p ϭ .04). There was a trend toward higher median PICU costs in the patients with CA-BSI, although the difference was not statistically significant (CA-BSI: $134,333 vs. non-CA-BSI: $80,531; p ϭ .06). Median total hospital costs, on the other hand, were significantly increased in CA-BSI patients (CA-BSI: $185,397 vs. non-CA-BSI: $152,358; p ϭ .048). The median total cost difference was $33,039 greater in CA-BSI patients compared with patients without CA-BSI (Table 1) . Three patients in the cohort died before hospital discharge (one BSI patient and two control patients). One control patient died before discharge from the PICU. There were no significant differences in either PICU mortality or hospital mortality between the two groups ( Table 1) .
CA-BSI Rate Data: FY 2006 Through FY 2009
Since March 2006, our PICU has been part of an institution-wide, multidisciplinary critical care unit quality improvement collaborative involving the PICU, cardiac intensive care unit, and the Regional Center for Neonatal Intensive Care, which has focused on reducing or eliminating hospital-acquired infections, including CA-BSI, ventilator-associated pneumonia (22) , and catheter-associated urinary tract infection. In September 2006, our PICU joined the 60 PICU quality improvement collaborative sponsored by the National Association of Children's Hospitals and Related Institutions. The aim of this collaborative was to eliminate CA-BSI. Both the critical care unit quality improvement collaborative and National Association of Children's Hospitals and Related Institutions established evidence (where available) or expert consensus-based clinical care practice bundles for central catheter insertion and maintenance care ( The aggregate cumulative hospital costs increased steadily for the CA-BSI patients and were $4,147,774 higher than those for the non-CA-BSI control patients. CA-BSI patients also spent an aggregate 572 more days in the hospital than the non-CA-BSI control patients. This reduction in the PICU CA-BSI rate decreased the total aggregate hospital LOS by 354 days, reduced total aggregate hospital costs by $1,298,271, and reduced the total aggregate costs to payers by $1,415,676 (Table 3) .
CA-BSI Patient Revenue Profile Analysis
There is a perception that quality improvement efforts may actually reduce hospital revenues through a reduction in hospital LOS (23, 24) . A "business case for quality" exists when quality improvement efforts result in increased profit, reduction in losses, or cost avoidance (25) . Again, in our cohort, patients with CA-BSI had a significantly longer total hospital LOS (median, 31.0 days; IQR, 17.0 -99.0) compared with patients without CA-BSI (median, 22.0 days; IQR, 13.0 -67.0; p ϭ .04), which resulted in a higher median total net revenue (CA-BSI: $202,163 vs. non-CA-BSI: $166,136; p ϭ .048). There was no significant difference in the median net revenue per patient day (CA-BSI: $6521 vs. non-CA-BSI: $7552) (Fig. 2) . As such, on the surface, it would seem that reduction of CA-BSI through our quality improvement efforts may have actually reduced revenue to the hospital, making it difficult to argue for a business case.
A more in-depth analysis comparing only the first 22 days of hospitalization (i.e., the median hospital LOS for non-CA-BSI patients), however, showed that the median net revenues per patient differed by only 2% ($3260) (CA-BSI: $166,136 vs. non-CA-BSI: $162,876). Therefore, the additional net revenue ($39,287) generated by a CA-BSI patient compared with a non-CA-BSI patient can be attributed to the CA-BSI patient's additional 9 days of stay in the hospital. Importantly, the amount of additional net revenue per day ($4,365) generated during these additional 9 days (i.e., hospital days, 22-31) was substantially lower than the amount of net revenue per day generated by either the non-CA-BSI patient ($7552 per day) or the CA-BSI patient ($7403 per day) during the first 22 days of the hospital stay. In other words, although the CA-BSI patients overall generated significantly more net hospital revenues compared with the non-CA-BSI patients (again, largely due to the longer hospital LOS in this group), the additional days spent in the hospital (i.e., days 22-31) generated significantly less net revenue per day compared with the first 22 days spent in the hospital for either group of patients.
The analysis above suggests that more net revenue is generated during the initial part of the hospital stay compared with the latter part of the hospital stay (Fig. 2) . Quality improvement efforts directed at reducing CA-BSI can shorten hospital LOS, thereby opening up additional hospital beds. These additional hospital beds may then be filled with new patients who are still in the initial phase of higher hospital revenue production. Based on this analysis, we next compared the net revenue generated by a single inpatient bed filled with a CA-BSI patient vs. a non-CA-BSI patient. If a single inpatient bed was filled with ten CA-BSI patients, they would occupy that bed for a total of 310 days (based on our median hospital LOS of 31 days) and generate $2,021,628 in net revenue (Fig. 3) . However, if we filled that same bed for the same length of time (310 days) with only non-CA-BSI patients, 14 additional patients (based on our median hospital LOS of 22 days for non-CA-BSI patients) could be admitted to the hospital, generating $2,325,904 in net revenue-this represents an additional $304,276 increase in hospital revenue than a bed filled with only CA-BSI patients for the same length of time (Fig. 4) .
DISCUSSION
We examined the differences in 22 CA-BSI patients and 22 matched control patients to determine whether CA-BSI was associated with increased LOS and hospital costs in critically ill children. Our analysis indicates there are statistically significant differences in hospital LOS, PICU LOS, and hospital costs in critically ill children with CA-BSI. In our cohort, the presence of CA-BSI extended the entire hospital LOS by 9 days (6.5 days while in the PICU) and increased hospital costs by $33,039, primarily driven by the increase in LOS days. The results of our study are consistent with the previous studies (3) (4) (5) , showing that hospitalacquired BSI increases LOS and costs, although the differences in LOS and total hospital costs are slightly smaller. However, the previous studies analyzed all patients with hospital-acquired BSI, not just CA-BSI. Our study is, therefore, the first study to demonstrate that CA-BSI are associated with increased hospital costs in the pediatric population.
We believe that our study is the first to document the impact of CA-BSI in critically ill children and demonstrate a positive business case for a quality intervention to prevent CA-BSI. This is also the first business case analysis explored from an institutional perspective that does not examine the impact of BSI reduction solely from the perspective of cost reduction; rather, this analysis also examines the revenue opportunities presented by eliminating preventable infections and their related incremental stays with freed capacity to treat other patients. As CA-BSI are prevented, a business case could certainly be made by eliminating costs (i.e., space, staffing, equipment, and supplies) associated with freed capacity. Alternatively, in a market with ever growing demand for inpatient resources, a business case could be made to redeploy resources freed up by prevented CA-BSI to care for new incoming patient populations. This later approach is an important and novel perspective because it demonstrates how eliminating excess infectionrelated hospital days can lead to increased revenues and improved asset realization.
Because every hospital or PICU day does not come at the same price, it is important to understand how revenue and costs are distributed during a patient's hospital stay to fully measure the potential impact of this type of quality improvement. We analyzed and charted the net revenue generated per day, or net revenue profile, for CA-BSI patients and matched control patients, using their median net revenue and median LOS (Fig. 2) . The net revenue profiles of these study patients can be characterized by two distinct periods of a patient's hospital stay. The first period of the hospital stay generated the highest revenue per day due to patients undergoing surgery (or other procedures) within the first days of their stay. The majority of revenue for a patient's entire hospital stay is generated during this period, steeply declining each day after the Figure 2 . Comparison of the net revenue generated per day, or net revenue profiles of (A) patient with catheter-associated bloodstream infections (CA-BSI) and (B) control patient with noncatheter-associated bloodstream infections (non-CA-BSI). Illustration of the two distinct periods of a patient's hospital stay, the first period with the highest revenue generation per day, steeply declining into the second period of steady but lower revenue generation per day. Comparing these profiles for CA-BSI and non-CA-BSI control patients demonstrates that the incremental length of stay attributed to CA-BSI extends the second period of the patient's hospital stay with lower net revenue per day, at the same time delaying the cycle of new patients who can be treated with these resources. initial procedures are completed. The second period is characterized by relatively steady but lower net revenue production per day, as less complex care is needed, leading up to the patient's discharge. Net revenues generated from this period are mainly from room/board and nursing charges, as few additional services are needed. The net revenue profiles of CA-BSI and non-CA-BSI control patients revealed nearly identical mean net revenue per day when comparing only hospital days where both patient types were admitted (i.e., days , with net revenue per day for the CA-BSI patient remaining low and stable for the CA-BSI patient on the days after the control patient discharge (days 23-31).
HIGHER REVENUE PRODUCTION
Non-CA-BSI Related Net Revenue: CA-BSI Related Net Revenue: Total Net Revenue: Days 1-22 Days 23-31 All
The net revenue profiles demonstrate that the incremental LOS attributed to CA-BSI generates lower net revenue per day at the same time delaying the cycle of new patients who can be treated with these resources. As CA-BSI lead to significantly increased LOS and costs, any decrease in the CA-BSI rate achieved at other institutions could offer substantial positive financial benefits but will differ by stakeholder, depending on the extent that freed capacity is needed to address new incoming patients. In a full redeployment scenario (i.e., 100% utilization of freed capacity from the CA-BSI), the hospital generates an incremental $304,276 in net revenue during the same period of time it previously took to care for ten CA-BSI patients (annualized incremental net revenue, $360,587). This illustrates the conversion of potential savings from preventing CA-BSI to real dollars, by replacing the lower net revenue days associated with the end of a CA-BSI patient's stay with the higher net revenue days associated with newly admitted patients. Third-party payers would also save $360,273 (annualized savings, $401,216) due to reduced CA-BSI-related billings, with no net difference in payments for replacement patients, because these patients would still require care elsewhere or at a later time. If it is assumed that full redeployment of the freed capacity from CA-BSI patients is not a likely outcome because capacity is not sufficiently constrained, a business case may still exist if the net revenue generated by new incoming patients equals the net revenue lost by preventing the CA-BSI and the hospital is successful in reducing some element of its cost structure. In our analysis, it would take only 48 days or 53% of the freed capacity to be redeployed to new incoming patients to equal the net revenue lost by preventing ten CA-BSI. In addition, it is important to note that, although capacity may exist in a hospital, overall, it is possible that, at the same time, certain specialized patient care units (such as the PICU) within that hospital are capacity-constrained. In that case, preventing CA-BSI may enable the specialized patient care units to admit new incoming patients, thereby producing the positive business case that was contemplated in this analysis.
In a zero redeployment scenario, where a hospital is able to prevent ten CA-BSI cases in PICU patients but does not redeploy capacity, the hospital would have potential cost savings of $330,394 (assumes all costs eliminated) from freeing up 90 hospital bed days, at the same time saving payers $360,273 in costs from reduced payments. In this scenario, the payer is the largest beneficiary, because there is an actual decrease in payments made for CA-BSI related billings. For the hospital, actual cost savings are difficult to estimate, depending on the extent they are able to eliminate the variable cost and fixed cost components.
The limitations of this study include its retrospective approach and small sample size drawn from a single hospital population. It is often difficult to generalize financial analysis results, because actual costs vary across institutions based on different personnel costs and different patterns of supply and pharmaceutical use. However, our use of costs rather than charges is preferred, as costs are considered a more reliable estimate of financial burden and more precisely describe institutional comparisons. In addition, this report is exclusively pediatric and may serve as comparison data for other similar pediatric institutions. We acknowledge the use of the matched control patient as the "replacement" patient positively impacted the financial benefits of preventing CA-BSI, because a control patient has slightly greater total net revenue during the hospital stay (i.e., days 1-22 ϭ $3260 difference). Thus, hospital incremental net revenues were overestimated by $45,640 (14 ϫ $3260) than if we used the CA-BSI patient's net revenue from days 1-22 as replacement patients. Results remained substantially positive in favor of CA-BSI prevention, but the incremental net revenue would have been slightly less if this was adjusted for ($304,276 vs. $258,636). Because we did not calculate the costs of the CA-BSI bundle implementation, there may also be implementation costs that partially offset the savings previously noted. Most authors (26) (27) (28) (29) have suggested that the benefit of CA-BSI prevention far outweighs implementation costs. Therefore, we believe these findings are likely to underestimate the true costs of CA-BSI, as they do not include nonhospital costs, such as those for follow-up visits with pediatricians, home care services, and medication prescriptions not filled at our hospital. Furthermore, we could not include the burden on families due to loss of earnings, family disruption, and the cost of pain, and/or disability. We also did not attempt to measure the impact of any functional deficits that occurred in CA-BSI patients.
CONCLUSION
This retrospective analysis indicates that the potential cost savings from reducing or eliminating CA-BSI in the PICU is significant. As payers and the government pressure the healthcare industry to reduce costs without reducing quality, there will be continued challenges for hospital management to find novel ways to reduce costs. Furthermore, third-party payer reimbursement for hospital-acquired infection-related charges will likely be eliminated in the future (30, 31) , leaving hospitals fully burdened with the expense caused by preventable CA-BSI. Elimination of CA-BSI will directly reduce hospital costs, improve asset utilization, and most importantly, improve clinical care. Remarkably, a CA-BSI increases, on average, length of pediatric ICU stay by 6.5 days and at the cost of over $33,000. Given that successful approach to produce a dramatic reduction in CA-BSI is well-recognized, this represents an important opportunity to both reduce cost and improve health care quality.
